Pharmaceuticals News and Research

RSS

Vion Pharmaceuticals files SPA for Onrigin-LDAC combination Phase II/III trial

VION PHARMACEUTICALS, INC. announced today that it had filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase II/III trial of its oncology therapeutic Onrigin™ (laromustine) Injection in combination with low-dose Ara-C (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML). The primary objective for the Phase III part of this study is to determine if Onrigin™ plus LDAC improves overall survival compared with LDAC alone.

12 Jan 2010

TTI enters into definitive license agreement with Biogen Idec

Trillium Therapeutics Inc. , a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into a definitive license agreement with Biogen Idec , granting the latter exclusive worldwide rights to one of Trillium's development programs.

12 Jan 2010

VaxInnate grants license to Biological E. to develop and commercialize recombinant H1N1 vaccine in India

VaxInnate Corporation today announced that it has granted Indian biopharmaceutical company Biological E. Limited a license to its recombinant H1N1 pandemic swine flu vaccine and is collaborating to facilitate the manufacture, clinical development and commercialization of the vaccine in India.

12 Jan 2010

GAO: Some meds had 'extraordinary' price hikes over past eight years

A report from the Government Accountability Office (GAO) issued Monday finds that "[p]rices on a growing number of prescription medications have ballooned in recent years as consolidation in the drug industry leaves fewer companies manufacturing niche medications," The Associated Press reports.

12 Jan 2010

Ibutilide Fumarate Injection launched

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals announced today the launch of Ibutilide Fumarate Injection, the generic equivalent of Corvert® from Pfizer Inc.

12 Jan 2010

miRagen Therapeutics establishes SAB

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today the formation of the company’s world renowned Scientific Advisory Board (SAB). The SAB was established to provide miRagen with valuable guidance in developing an extensive pipeline of microRNA-based drugs and is comprised of leaders who are internationally recognized experts in their respective fields.

12 Jan 2010

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 2, a Phase IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non Responders (INR) after at least 12 months of highly active anti-retroviral therapy (HAART).

12 Jan 2010

VentiRx Pharmaceuticals completes $25 million Series A Extension

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today the completion of a $25 million Series A Extension.

12 Jan 2010

Astro Pak announces the launch of new subsidiary, SixLog

Astro Pak Corporation, the U.S.'s largest precision cleaning and passivation company, today announced the launch of their new subsidiary, SixLog Corporation. SixLog provides on-site biological decontamination services utilizing proprietary iHP™ (ionized Hydrogen Peroxide) technology to a variety of industries including Life Sciences, Pharmaceutical, Healthcare, First Responders, Transportation, and Public Facilities.

12 Jan 2010

MedGenesis Therapeutix enters into license agreement with Amgen

MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.

12 Jan 2010

Madison Williams launches Healthcare Investment Banking and Research business

Madison Williams and Company, an integrated capital markets and advisory firm, announced today the formal launch of a focused Healthcare Investment Banking and Research business. Madison Williams recently completed a management buyout of the principal capital markets business from Sanders Morris Harris Group in December 2009. The new firm already has a leading franchise in the Energy sector, and is quickly establishing its presence in healthcare with key new hires.

12 Jan 2010

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

NanoViricides, Inc. (the "Company"), reports that the Company has been invited to present on January 12th at the Biotech Showcase™, a conference designed to showcase promising companies and technologies for partnering and investment purposes.

12 Jan 2010

Market for chronic tophaceous gout medications will be led by drug that resolves tophi in less than a year

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the U.S. and Europe, a drug that resolves tophi in less than one year would become the patient share leader in the chronic tophaceous gout patient subpopulation and would be used in the vast majority of patients who suffer severe tophaceous gout, according to surveyed U.S. and European rheumatologists.

12 Jan 2010

Pfizer/Medivation's AD drug Dimebon may garner peak year sales of $1.5 billion

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Pfizer/Medivation's Dimebon shows efficacy in two ongoing clinical trials in moderate to severe Alzheimer's disease that is equivalent to the impressive clinical trial data it has already shown to date in mild to moderate patients, these positive data would promote the use of Dimebon throughout the course of the disease.

12 Jan 2010

Stanford University School of Medicine adopts new, industry-funded model for continuing physicians’ education

Stanford University School of Medicine has developed a new, industry-funded model for the continuing education of physicians that aims to improve patient care while ensuring that corporate donors do not exert influence over the curriculum.

12 Jan 2010

Curemark retains Rubenstein Public Relations

Curemark, a drug research and development company that focuses on the treatment of neurological diseases, has retained Rubenstein Public Relations to help raise national, regional, and industry awareness of the organization's research, treatments and founder, Dr. Joan Fallon. Curemark is developing an autism treatment that will be one of the first to address the underlying physiology of autism.

12 Jan 2010

MRCT announces licensing deal for development of novel therapy for inflammatory and immune diseases

Georg-August-University Gottingen, University of Regensburg and MRC Technology (MRCT) have signed exclusive license agreements through MBM ScienceBridge GmbH and in agreement with Bayerische Patentallianz GmbH, for the development of a novel therapy of inflammatory and immune diseases based on the depletion of inflammatory monocytes. The first targets will be rheumatoid arthritis (RA) and multiple sclerosis (MS).

12 Jan 2010

New GAO report shows price increase for brand-name drugs doubles from 2000 to 2008

A new report from the Government Accountability Office (GAO) that finds “extraordinary price increases” for brand-name drug products from 2000 – 2008 was largely fueled by the “lack of therapeutically equivalent drugs” and “limited competition,” underscores the need for policymakers to promote policies in health reform which increase competition and lower costs, the Pharmaceutical Care Management Association (PCMA) said today.

12 Jan 2010

Integration demonstration between EHR platforms and Nextrials’ Prism EDC technology

Nextrials, Inc., a leader in clinical research software and services, will participate in an integration demonstration between its PrismTM, an award-winning clinical trial electronic data capture technology, and electronic health records (EHR) platforms used within healthcare systems at the 11th Annual IHE North America Connectathon, being held January 11-15 at the Hyatt Regency Chicago. The Connectathon is the healthcare IT industry’s largest interoperability testing event dedicated to establishing standards that address specific clinical needs in support of optimal patient care.

12 Jan 2010

Haemacure to make a proposal to its creditors under the Bankruptcy and Insolvency Act

Haemacure Corporation announces that it has filed a notice of intention to make a proposal to its creditors under the Bankruptcy and Insolvency Act (Canada) and that its wholly-owned U.S. subsidiary sought court protection under Chapter 11 in the United States. The filings were made after the close of markets on Friday, January 8, 2010.

12 Jan 2010

Pharmaceuticals News and Research

Vion Pharmaceuticals files SPA for Onrigin-LDAC combination Phase II/III trial

TTI enters into definitive license agreement with Biogen Idec

VaxInnate grants license to Biological E. to develop and commercialize recombinant H1N1 vaccine in India

GAO: Some meds had 'extraordinary' price hikes over past eight years

Ibutilide Fumarate Injection launched

miRagen Therapeutics establishes SAB

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

VentiRx Pharmaceuticals completes $25 million Series A Extension

Astro Pak announces the launch of new subsidiary, SixLog

MedGenesis Therapeutix enters into license agreement with Amgen

Madison Williams launches Healthcare Investment Banking and Research business

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

Market for chronic tophaceous gout medications will be led by drug that resolves tophi in less than a year

Pfizer/Medivation's AD drug Dimebon may garner peak year sales of $1.5 billion

Stanford University School of Medicine adopts new, industry-funded model for continuing physicians’ education

Curemark retains Rubenstein Public Relations

MRCT announces licensing deal for development of novel therapy for inflammatory and immune diseases

New GAO report shows price increase for brand-name drugs doubles from 2000 to 2008

Integration demonstration between EHR platforms and Nextrials’ Prism EDC technology

Haemacure to make a proposal to its creditors under the Bankruptcy and Insolvency Act

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence